Francisco J. Esteva

27.9k total citations · 5 hit papers
280 papers, 18.0k citations indexed

About

Francisco J. Esteva is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Francisco J. Esteva has authored 280 papers receiving a total of 18.0k indexed citations (citations by other indexed papers that have themselves been cited), including 207 papers in Oncology, 85 papers in Radiology, Nuclear Medicine and Imaging and 79 papers in Cancer Research. Recurrent topics in Francisco J. Esteva's work include HER2/EGFR in Cancer Research (138 papers), Monoclonal and Polyclonal Antibodies Research (67 papers) and Cancer Treatment and Pharmacology (59 papers). Francisco J. Esteva is often cited by papers focused on HER2/EGFR in Cancer Research (138 papers), Monoclonal and Polyclonal Antibodies Research (67 papers) and Cancer Treatment and Pharmacology (59 papers). Francisco J. Esteva collaborates with scholars based in United States, United Kingdom and Spain. Francisco J. Esteva's co-authors include Rita Nahta, Gabriel N. Hortobágyi, Mien‐Chie Hung, Dihua Yu, Lajos Pusztai, Ayşegül A. Şahin, Vicente Valero, Linda X.H. Yuan, Aman U. Buzdar and Massimo Cristofanilli and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nucleic Acids Research.

In The Last Decade

Francisco J. Esteva

277 papers receiving 17.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

2004 1.4k citations Francisco J. Esteva, Ayşegül A. Şahin et al. profile →
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

2006 696 citations Rita Nahta, Mien‐Chie Hung et al. profile →
Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells

2005 584 citations Rita Nahta, Linda X.H. Yuan et al. Cancer Research profile →
Immunotherapy and targeted therapy combinations in metastatic breast cancer

2019 336 citations Francisco J. Esteva, Vanessa M. Hubbard-Lucey et al. The Lancet Oncology profile →
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

2020 280 citations Francisco J. Esteva et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francisco J. Esteva United States	68	11.6k	7.0k	4.9k	4.6k	3.2k	280	18.0k
Brian Leyland‐Jones United States	53	11.6k 1.0×	5.7k 0.8×	4.1k 0.8×	4.6k 1.0×	3.3k 1.0×	218	18.4k
Steven Wong United States	17	11.5k 1.0×	6.6k 0.9×	6.6k 1.3×	3.0k 0.7×	2.0k 0.6×	36	16.0k
John Crown Ireland	71	13.0k 1.1×	7.4k 1.1×	2.4k 0.5×	6.0k 1.3×	4.8k 1.5×	416	20.1k
Lyndsay N. Harris United States	53	9.3k 0.8×	5.1k 0.7×	3.0k 0.6×	5.5k 1.2×	2.9k 0.9×	192	15.0k
Mark D. Pegram United States	56	17.8k 1.5×	6.8k 1.0×	8.5k 1.7×	4.9k 1.1×	4.6k 1.4×	221	23.8k
Wendy J. Levin United States	14	11.5k 1.0×	6.5k 0.9×	6.6k 1.3×	2.8k 0.6×	2.0k 0.6×	36	15.8k
Sandra M. Swain United States	66	15.4k 1.3×	5.1k 0.7×	4.9k 1.0×	7.2k 1.6×	4.8k 1.5×	337	23.4k
Ian E. Krop United States	68	13.9k 1.2×	4.7k 0.7×	5.7k 1.2×	4.0k 0.9×	5.4k 1.7×	298	19.0k
John M.S. Bartlett United Kingdom	60	10.5k 0.9×	6.2k 0.9×	4.1k 0.8×	7.0k 1.5×	3.7k 1.2×	310	18.8k
Evandro de Azambuja Belgium	58	10.7k 0.9×	3.1k 0.4×	2.5k 0.5×	4.7k 1.0×	3.6k 1.1×	351	15.4k

Countries citing papers authored by Francisco J. Esteva

Since Specialization

Citations

This map shows the geographic impact of Francisco J. Esteva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco J. Esteva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco J. Esteva more than expected).

Fields of papers citing papers by Francisco J. Esteva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisco J. Esteva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco J. Esteva. The network helps show where Francisco J. Esteva may publish in the future.

Co-authorship network of co-authors of Francisco J. Esteva

This figure shows the co-authorship network connecting the top 25 collaborators of Francisco J. Esteva. A scholar is included among the top collaborators of Francisco J. Esteva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisco J. Esteva. Francisco J. Esteva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, Xuexin, Jiali Ji, Mei Tian, et al.. (2019). Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. Clinical Cancer Research. 25(24). 7388–7395. 15 indexed citations

Fu, Chen, Justin Stebbing, & Francisco J. Esteva. (2019). Clinical development of CT-P6 in HER2 positive breast cancer. Expert Opinion on Biological Therapy. 19(10). 987–992. 6 indexed citations

Esteva, Francisco J., Vanessa M. Hubbard-Lucey, Jun Tang, & Lajos Pusztai. (2019). Immunotherapy and targeted therapy combinations in metastatic breast cancer. The Lancet Oncology. 20(3). e175–e186. 336 indexed citations breakdown →

Janni, Wolfgang, Emilio Alba, Thomas Bachelot, et al.. (2018). First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Research and Treatment. 169(3). 469–479. 35 indexed citations

Lipton, Allan, Kim Leitzel, Suhail M. Ali, et al.. (2018). High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. International Journal of Cancer. 143(11). 3027–3034. 45 indexed citations

Stebbing, Justin, Alexey Manikhas, Vladimir Moiseyenko, et al.. (2017). CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. The Lancet Oncology. 18(7). 917–928. 94 indexed citations

Esteva, Francisco J.. (2015). Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis.. PubMed. 13(6 Suppl 6). 25–31. 3 indexed citations

Jhaveri, Komal, et al.. (2014). Genome-Based Risk Prediction for Early Stage Breast Cancer. The Oncologist. 19(10). 1019–1027. 5 indexed citations

Magbanua, Mark Jesus M., Lisa A. Carey, Amy DeLuca, et al.. (2014). Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research. 21(5). 1098–1105. 32 indexed citations

10.

Giordano, Sharon H., Sarah Temin, Jeffrey J. Kirshner, et al.. (2014). Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2078–2099. 258 indexed citations

11.

Pusztai, Lajos, Stacy L. Moulder, Mehmet Altan, et al.. (2014). Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research. 20(20). 5265–5271. 28 indexed citations

12.

Murthy, Rashmi K., Ankur Varma, Kenneth R. Hess, et al.. (2014). Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer. Cancer. 120(13). 1932–1938. 33 indexed citations

13.

Kuerer, Henry M., Aman U. Buzdar, Elizabeth A. Mittendorf, et al.. (2010). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 117(1). 39–47. 48 indexed citations

14.

Johnson, Peter H. & Francisco J. Esteva. (2007). The use of HER2 modulation in the adjuvant setting. Current Oncology Reports. 9(1). 9–16. 3 indexed citations

15.

Esteva, Francisco J., Jing Wang, Feng Lin, et al.. (2007). CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Research. 9(6). R87–R87. 31 indexed citations

16.

Itamochi, Hiroaki, Linda X.H. Yuan, Francisco J. Esteva, et al.. (2005). Bcl-2 Antisense Oligonucleotide Overcomes Resistance toE1AGene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. Cancer Research. 65(18). 8406–8413. 18 indexed citations

17.

Nahta, Rita, Gabriel N. Hortobágyi, & Francisco J. Esteva. (2003). Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention. The Oncologist. 8(1). 5–17. 91 indexed citations

18.

Esteva, Francisco J., Ayşegül A. Şahin, George Z. Rassidakis, et al.. (2003). Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.. PubMed. 9(15). 5652–9. 63 indexed citations

19.

Tari, Ana M., Soo-Jeong Lim, Mien‐Chie Hung, Francisco J. Esteva, & Gabriel Lopez‐Berestein. (2002). Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 21(34). 5224–5232. 63 indexed citations

20.

Livingston, Robert B. & Francisco J. Esteva. (2001). Chemotherapy and Herceptin for HER-2+ Metastatic Breast Cancer: The Best Drug?. The Oncologist. 6(4). 315–316. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact